These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 19142633)

  • 1. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease.
    Mosconi L; Mistur R; Switalski R; Tsui WH; Glodzik L; Li Y; Pirraglia E; De Santi S; Reisberg B; Wisniewski T; de Leon MJ
    Eur J Nucl Med Mol Imaging; 2009 May; 36(5):811-22. PubMed ID: 19142633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of amnestic patients with hypometabolism patterns suggestive of Lewy body pathology.
    Silva-Rodríguez J; Labrador-Espinosa MA; Moscoso A; Schöll M; Mir P; Grothe MJ;
    Brain; 2023 Nov; 146(11):4520-4531. PubMed ID: 37284793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantifying brain metabolism from FDG-PET images into a probability of Alzheimer's dementia score.
    Yee E; Popuri K; Beg MF;
    Hum Brain Mapp; 2020 Jan; 41(1):5-16. PubMed ID: 31507022
    [No Abstract]   [Full Text] [Related]  

  • 4. Accelerated hypometabolism with disease progression associated with faster cognitive decline among amyloid positive patients.
    Yang Z; Cummings JL; Kinney JW; Cordes D;
    Front Neurosci; 2023; 17():1151820. PubMed ID: 37123373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implication of metabolic and dopamine transporter PET in dementia with Lewy bodies.
    Kang SW; Jeon S; Lee YG; Park M; Baik K; Jung JH; Chung SJ; Yoo HS; Jeong SH; Yun M; Lee PH; Sohn YH; Evans AC; Ye BS
    Sci Rep; 2021 Jul; 11(1):14394. PubMed ID: 34257349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).
    de Leon MJ; Convit A; Wolf OT; Tarshish CY; DeSanti S; Rusinek H; Tsui W; Kandil E; Scherer AJ; Roche A; Imossi A; Thorn E; Bobinski M; Caraos C; Lesbre P; Schlyer D; Poirier J; Reisberg B; Fowler J
    Proc Natl Acad Sci U S A; 2001 Sep; 98(19):10966-71. PubMed ID: 11526211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative.
    Chen K; Langbaum JB; Fleisher AS; Ayutyanont N; Reschke C; Lee W; Liu X; Bandy D; Alexander GE; Thompson PM; Foster NL; Harvey DJ; de Leon MJ; Koeppe RA; Jagust WJ; Weiner MW; Reiman EM;
    Neuroimage; 2010 Jun; 51(2):654-64. PubMed ID: 20202480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebral glucose metabolic correlates of cognitive and behavioural impairments in amyotrophic lateral sclerosis.
    Lehto A; Schumacher J; Kasper E; Teipel S; Hermann A; Kurth J; Krause BJ; Prudlo J
    J Neurol; 2024 Aug; 271(8):5290-5300. PubMed ID: 38861034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism.
    Mosconi L; Brys M; Switalski R; Mistur R; Glodzik L; Pirraglia E; Tsui W; De Santi S; de Leon MJ
    Proc Natl Acad Sci U S A; 2007 Nov; 104(48):19067-72. PubMed ID: 18003925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late-onset epilepsy with cognitive symptoms: Comparison of cognitive and imaging profiles with probable Alzheimer's disease.
    Zhang X; Ahmed R; Thayer Z; Breen N; McMillan J; Fulham M; Nikpour A
    Epilepsy Behav; 2023 Sep; 146():109371. PubMed ID: 37556966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential diagnosis of amnestic dementia patients based on an FDG-PET signature of autopsy-confirmed LATE-NC.
    Grothe MJ; Moscoso A; Silva-Rodríguez J; Lange C; Nho K; Saykin AJ; Nelson PT; Schöll M; Buchert R; Teipel S;
    Alzheimers Dement; 2023 Apr; 19(4):1234-1244. PubMed ID: 35971593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case report: pre-symptomatic clinical and metabolic profile in posterior cortical atrophy and dementia with Lewy bodies.
    Shir D; Corriveau-Lecavalier N; Graff-Radford J; Machulda MM; Knopman DS; Petersen RC; Nguyen AT; Dickson DW; Jones DT
    Neurocase; 2024 Feb; 30(1):1-7. PubMed ID: 38758704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multi-center randomized proof-of-concept clinical trial applying [¹⁸F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease.
    Tzimopoulou S; Cunningham VJ; Nichols TE; Searle G; Bird NP; Mistry P; Dixon IJ; Hallett WA; Whitcher B; Brown AP; Zvartau-Hind M; Lotay N; Lai RY; Castiglia M; Jeter B; Matthews JC; Chen K; Bandy D; Reiman EM; Gold M; Rabiner EA; Matthews PM
    J Alzheimers Dis; 2010; 22(4):1241-56. PubMed ID: 20930300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blinded Clinical Evaluation for Dementia of Alzheimer's Type Classification Using FDG-PET: A Comparison Between Feature-Engineered and Non-Feature-Engineered Machine Learning Methods.
    Ma D; Yee E; Stocks JK; Jenkins LM; Popuri K; Chausse G; Wang L; Probst S; Beg MF
    J Alzheimers Dis; 2021; 80(2):715-726. PubMed ID: 33579858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebral Glucose Metabolism Is a Valuable Predictor of Survival in Patients with Lewy Body Diseases.
    Brumberg J; Blazhenets G; Bühler S; Fostitsch J; Rijntjes M; Ma Y; Eidelberg D; Weiller C; Jost WH; Frings L; Schröter N; Meyer PT
    Ann Neurol; 2024 Sep; 96(3):539-550. PubMed ID: 38888141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebral glucose metabolism in Alzheimer's disease.
    Salmon E; Collette F; Bastin C
    Cortex; 2024 Oct; 179():50-61. PubMed ID: 39141935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Occipital Pole" Sign on 18 F-FDG PET for Dementia With Lewy Bodies and Posterior Cortical Atrophy : Evidence From the Treviso Dementia (TREDEM) Registry.
    Gallucci M; Fiore V; Grassivaro F; Da Ronch C; Bonanni L
    Clin Nucl Med; 2022 Sep; 47(9):811-812. PubMed ID: 35473924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evoked potentials and neuropsychological tests validate Positron Emission Topography (PET) brain metabolism in cognitively impaired patients.
    Braverman ER; Blum K; Damle UJ; Kerner M; Dushaj K; Oscar-Berman M
    PLoS One; 2013; 8(3):e55398. PubMed ID: 23526928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between brain glucose metabolism and insulin resistance in subjects with normal cognition - a study based on 18F-FDG PET.
    Chen Y; Qiu C; Yu W; Shao X; Zhou M; Wang Y; Shao X
    Nucl Med Commun; 2022 Mar; 43(3):275-283. PubMed ID: 34816810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimer's disease: a series of clinical cases.
    Corriveau-Lecavalier N; Machulda MM; Botha H; Graff-Radford J; Knopman DS; Lowe VJ; Fields JA; Stricker NH; Boeve BF; Jack CR; Petersen RC; Jones DT
    J Neurol; 2022 Aug; 269(8):4110-4128. PubMed ID: 35211780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.